P27 Kip1 represses transcription by direct interaction with p130/E2F4 at the promoters of target genes

Oncogene

Volumn 31, Issue 38, 2012, Pages 4207-4220

  Pippa, R ^a   Espinosa, L ^b   Gundem, G ^c   Garcia Escudero R ^d   Dominguez, A ^a   Orlando, S ^a   Gallastegui, E ^a   Saiz, C ^d   Besson, A ^e   Pujol, M J ^a   Lopez Bigas N ^c   Paramio, J M ^d   Bigas, A ^b   Bachs, O ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL DEL MAR   (Spain)

^c UNIVERSITAT POMPEU FABRA   (Spain)

^d CIEMAT   (Spain)

^e CANCER RESEARCH CENTER OF TOULOUSE   (France)

Author keywords

E2F4; p130; p27; transcription

Indexed keywords

HISTONE DEACETYLASE; PROTEIN P130; PROTEIN P27; TRANSCRIPTION FACTOR E2F4; TRANSCRIPTION FACTOR SIN3A; COREPRESSOR PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1B;

AFFINITY CHROMATOGRAPHY; ANIMAL CELL; ARTICLE; CARCINOGENESIS; CELL CYCLE; CELL FUNCTION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; ENZYME ASSAY; GENE FUNCTION; GENE INTERACTION; GENE LOCATION; GENE OVEREXPRESSION; GENE STRUCTURE; GENETIC ASSOCIATION; GENETIC TRANSCRIPTION; MICROARRAY ANALYSIS; MITOCHONDRIAL RESPIRATION; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; RNA PROCESSING; RNA SPLICING; RNA TRANSLATION; TRANSCRIPTION REGULATION; ANIMAL; BIOLOGICAL MODEL; CELL STRAIN 3T3; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; MORTALITY; MOUSE; NEOPLASM; PROGNOSIS; PROTEIN BINDING;

ANIMALS; CO-REPRESSOR PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; E2F4 TRANSCRIPTION FACTOR; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MODELS, BIOLOGICAL; NEOPLASMS; NIH 3T3 CELLS; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; RETINOBLASTOMA-LIKE PROTEIN P130; TRANSCRIPTION, GENETIC;

EID: 84861463956     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.582     Document Type: Article

References (58)

1. Acosta JC, Ferrandiz N, Bretones G, Torrano V, Blanco R, Richard C et al. (2008). Myc inhibits p27-induced erythroid differentiation of leukemia cells by repressing erythroid master genes without reversing p27-mediated cell cycle arrest. Mol Cell Biol 28: 7286-7295.
2. Aguilera C, Hoya-Arias R, Haegeman G, Espinosa L, Bigas A. (2004). Recruitment of IkappaBalpha to the hes1 promoter is associated with transcriptional repression. Proc Natl Acad Sci USA 101: 16537-16542. (Pubitemid 39557748)
3. Baldassarre G, Belletti B, Nicoloso MS, Schiappacassi M, Vecchione A, Spessotto P et al. (2005). p27(Kip1)-stathmin interaction influences sarcoma cell migration and invasion. Cancer Cell 7: 51-63. (Pubitemid 40126382)
4. Benjamini Y, Hochberg Y. (1995). Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B (Methodol) 57: 289-300.
5. Besson A, Dowdy SF, Roberts JM. (2008). CDK inhibitors: cell cycle regulators and beyond. Dev Cell 14: 159-169. (Pubitemid 351189186)
6. Besson A, Gurian-West M, Schmidt A, Hall A, Roberts JM. (2004). p27Kip1 modulates cell migration through the regulation of RhoA activation. Genes Dev 18: 862-876. (Pubitemid 38529656)
7. Besson A, Hwang HC, Cicero S, Donovan SL, Gurian-West M, Johnson D et al. (2007). Discovery of an oncogenic activity in p27Kip1 that causes stem cell expansion and a multiple tumor phenotype. Genes Dev 21: 1731-1746. (Pubitemid 47076473)
8. Blain SW. (2008). Switching cyclin D-Cdk4 kinase activity on and off. Cell Cycle 7: 892-898. (Pubitemid 351573783)
9. Blanco E, Messeguer X, Smith TF, Guigo R. (2006). Transcription factor map alignment of promoter regions. PLoS Comput Biol 2: e49.
10. Brune V, Tiacci E, Pfeil I, Doring C, Eckerle S, van Noesel CJ et al. (2008). Origin and pathogenesis of nodular lymphocyte-predominant Hodgkin lymphoma as revealed by global gene expression analysis. J Exp Med 205: 2251-2268.
11. Carter BZ, Mak DH, Shi Y, Schober WD, Wang RY, Konopleva M et al. (2006). Regulation and targeting of Eg5, a mitotic motor protein in blast crisis CML: overcoming imatinib resistance. Cell Cycle 5: 2223-2229. (Pubitemid 44546558)
12. Casey T, Bond J, Tighe S, Hunter T, Lintault L, Patel O et al. (2009). Molecular signatures suggest a major role for stromal cells in development of invasive breast cancer. Breast Cancer Res Treat 114: 47-62.
13. Chu I, Sun J, Arnaout A, Kahn H, Hanna W, Narod S et al. (2007). p27 phosphorylation by Src regulates inhibition of cyclin E-Cdk2. Cell 128: 281-294. (Pubitemid 46123510)
14. Chu IM, Hengst L, Slingerland JM. (2008). The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer 8: 253-267. (Pubitemid 351430863)
15. Cobrinik D, Lee MH, Hannon G, Mulligan G, Bronson RT, Dyson N et al. (1996). Shared role of the pRB-related p130 and p107 proteins in limb development. Genes Dev 10: 1633-1644. (Pubitemid 26268868)
16. Fero ML, Rivkin M, Tasch M, Porter P, Carow CE, Firpo E et al. (1996). A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice. Cell 85: 733-744.
17. Flicek P, Aken BL, Beal K, Ballester B, Caccamo M, Chen Y et al. (2008). Ensembl 2008. Nucleic Acids Res 36: D707-D714. (Pubitemid 351149811)
18. Frescas D, Pagano M. (2008). Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancer. Nat Rev Cancer 8: 438-449. (Pubitemid 351744963)
19. Grimmler M, Wang Y, Mund T, Cilensek Z, Keidel EM, Waddell MB et al. (2007). Cdk-inhibitory activity and stability of p27Kip1 are directly regulated by oncogenic tyrosine kinases. Cell 128: 269-280. (Pubitemid 46123508)
20. Gundem G, Perez-Llamas C, Jene-Sanz A, Kedzierska A, Islam A, Deu-Pons J et al. (2010). IntOGen: integration and data mining of multidimensional oncogenomic data. Nat Methods 7: 92-93.
21. Gutierrez NC, Ocio EM, de Las Rivas J, Maiso P, Delgado M, Ferminan E et al. (2007). Gene expression profiling of B lymphocytes and plasma cells from Waldenstrom's macroglobuli-nemia: comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individuals. Leukemia 21: 541-549.
22. Hollenhorst PC, Shah AA, Hopkins C, Graves BJ. (2007). Genome-wide analyses reveal properties of redundant and specific promoter occupancy within the ETS gene family. Genes Dev 21: 1882-1894. (Pubitemid 47204928)
23. Huszar D, Theoclitou ME, Skolnik J, Herbst R. (2009). Kinesin motor proteins as targets for cancer therapy. Cancer Metastasis Rev 28: 197-208.
24. James MK, Ray A, Leznova D, Blain SW. (2008). Differential modification of p27Kip1 controls its cyclin D-cdk4 inhibitory activity. Mol Cell Biol 28: 498-510.
25. Jones MH, Virtanen C, Honjoh D, Miyoshi T, Satoh Y, Okumura S et al. (2004). Two prognostically significant subtypes of high-grade lung neuroendocrine tumours independent of small-cell and large-cell neuroendocrine carcinomas identified by gene expression profiles. Lancet 363: 775-781. (Pubitemid 38315167)
26. Kiyokawa H, Kineman RD, Manova-Todorova KO, Soares VC, Hoffman ES, Ono M et al. (1996). Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27(Kip1). Cell 85: 721-732.
27. Lapenna S, Giordano A. (2009). Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov 8: 547-566.
28. Lopez-Bigas N, Kisiel TA, Dewaal DC, Holmes KB, Volkert TL, Gupta S et al. (2008). Genome-wide analysis of the H3K4 histone demethylase RBP2 reveals a transcriptional program controlling differentiation. Mol Cell 31: 520-530.
29. Lowry OH, Rosenbrough NJ, Farr AL, Randall RJ. (1951). Protein measurement with the folin-phenol reagent. J Biol Chem 193: 165-175.
30. Macaluso M, Montanari M, Giordano A. (2006). Rb family proteins as modulators of gene expression and new aspects regarding the interaction with chromatin remodeling enzymes. Oncogene 25: 5263-5267. (Pubitemid 44299086)
31. Malumbres M, Barbacid M. (2005). Mammalian cyclin-dependent kinases. Trends Biochem Sci 30: 630-641. (Pubitemid 41540083)
32. Malumbres M, Barbacid M. (2007). Cell cycle kinases in cancer. Curr Opin Genet Dev 17: 60-65. (Pubitemid 46109297)
33. Matys V, Fricke E, Geffers R, Gossling E, Haubrock M, Hehl R et al. (2003). TRANSFAC: transcriptional regulation, from patterns to profiles. Nucleic Acids Res 31: 374-378. (Pubitemid 36150406)
34. McAllister SS, Becker-Hapak M, Pintucci G, Pagano M, Dowdy SF. (2003). Novel p27(kip1) C-terminal scatter domain mediates Rac-dependent cell migration independent of cell cycle arrest functions. Mol Cell Biol 23: 216-228. (Pubitemid 36008515)
35. Munoz-Alonso MJ, Acosta JC, Richard C, Delgado MD, Sedivy J, Leon J. (2005). p21Cip1 and p27Kip1 induce distinct cell cycle effects and differentiation programs in myeloid leukemia cells. J Biol Chem 280: 18120-18129. (Pubitemid 41389057)
36. Nakayama K, Ishida N, Shirane M, Inomata A, Inoue T, Shishido N et al. (1996). Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 85: 707-720.
37. Nguyen L, Besson A, Heng JI, Schuurmans C, Teboul L, Parras C et al. (2006). p27kip1 independently promotes neuronal differentiation and migration in the cerebral cortex. Genes Dev 20: 1511-1524. (Pubitemid 43830657)
38. Pawitan Y, Bjohle J, Amler L, Borg AL, Egyhazi S, Hall P et al. (2005). Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res 7: R953-R964.
39. Perez-Llamas C, Lopez-Bigas N. (2011). Gitools: analysis and visualisation of genomic data using interactive heat-maps. PLoS One 6: e19541.
40. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD et al. (2006). Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9: 157-173. (Pubitemid 43357943)
41. Piccaluga PP, Agostinelli C, Califano A, Rossi M, Basso K, Zupo S et al. (2007). Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets. J Clin Invest 117: 823-834. (Pubitemid 46348541)
42. Pyeon D, Newton MA, Lambert PF, den Boon JA, Sengupta S, Marsit CJ et al. (2007). Fundamental differences in cell cycle deregulation in human papillomavirus-positive and human papillo-mavirus-negative head/neck and cervical cancers. Cancer Res 67: 4605-4619. (Pubitemid 46910165)
43. Rayman JB, Takahashi Y, Indjeian VB, Dannenberg JH, Catchpole S, Watson RJ et al. (2002). E2F mediates cell cycle-dependent transcriptional repression in vivo by recruitment of an HDAC1/mSin3B corepressor complex. Genes Dev 16: 933-947. (Pubitemid 34408543)
44. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D et al. (2004). ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 6: 1-6. (Pubitemid 38391943)
45. Richardson AL, Wang ZC, De Nicolo A, Lu X, Brown M, Miron A et al. (2006). X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell 9: 121-132. (Pubitemid 43202662)
46. Russo AA, Jeffrey PD, Patten AK, Massague J, Pavletich NP. (1996). Crystal structure of the p27Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex. Nature 382: 325-331. (Pubitemid 26260452)
47. Sabates-Bellver J, Van der Flier LG, de Palo M, Cattaneo E, Maake C, Rehrauer H et al. (2007). Transcriptome profile of human colorectal adenomas. Mol Cancer Res 5: 1263-1275.
48. Saijo T, Ishii G, Ochiai A, Yoh K, Goto K, Nagai K et al. (2006). Eg5 expression is closely correlated with the response of advanced non-small cell lung cancer to antimitotic agents combined with platinum chemotherapy. Lung Cancer 54: 217-225. (Pubitemid 44764912)
49. Shedden K, Taylor JM, Enkemann SA, Tsao MS, Yeatman TJ, Gerald WL et al. (2008). Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med 14: 822-827.
50. Sherr CJ, Roberts JM. (1999). CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13: 1501-1512. (Pubitemid 29297917)
51. Shirane M, Harumiya Y, Ishida N, Hirai A, Miyamoto C, Hatakeyama S et al. (1999). Down-regulation of p27(Kip1) by two mechanisms, ubiquitin-mediated degradation and proteolytic processing. J Biol Chem 274: 13886-13893. (Pubitemid 129518688)
52. Sicinski P, Zacharek S, Kim C. (2007). Duality of p27Kip1 function in tumorigenesis. Genes Dev 21: 1703-1706.
53. Slingerland J, Pagano M. (2000). Regulation of the cdk inhibitor p27 and its deregulation in cancer. J Cell Physiol 183: 10-17. (Pubitemid 30130220)
54. Smyth GK. (2004). Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3: article 3.
55. Soeiro I, Mohamedali A, Romanska HM, Lea NC, Child ES, Glassford J et al. (2006). p27Kip1 and p130 cooperate to regulate hematopoietic cell proliferation in vivo. Mol Cell Biol 26: 6170-6184. (Pubitemid 44204535)
56. Vera J, Estanyol JM, Canela N, Llorens F, Agell N, Itarte E et al. (2007). Proteomic analysis of SET-binding proteins. Proteomics 7: 578-587. (Pubitemid 46362621)
57. Viglietto G, Motti ML, Bruni P, Melillo RM, D'Alessio A, Califano D et al. (2002). Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. Nat Med 8: 1136-1144. (Pubitemid 35175969)
58. Yeh N, Miller JP, Gaur T, Capellini TD, Nikolich-Zugich J, de la HC et al. (2007). Cooperation between p27 and p107 during endochon-dral ossification suggests a genetic pathway controlled by p27 and p130. Mol Cell Biol 27: 5161-5171. (Pubitemid 47068290)